Table 2.
Characteristics of first cryoablation, baseline immune markers of peripheral blood, and 3-month ORR (n = 45)
| Category | Non-response | Response | P value |
|---|---|---|---|
| Diameter of lesions ablated | 0.283* | ||
| ≤ 30 | 20 (60.6) | 10 (83.3) | |
| > 30 | 13 (39.4) | 2 (16.7) | |
| Number of lesions ablated | 0.524 | ||
| 1 | 20 (60.6) | 6 (50.0) | |
| 2–4 | 13 (39.4) | 6 (50.0) | |
| Number of cryoablation needles | 0.699* | ||
| ≤ 2 | 24 (72.7) | 10 (83.3) | |
| > 2 | 9 (27.3) | 2 (16.7) | |
| Time from liver metastasis to first cryoablation (months) | 0.325* | ||
| ≤ 0.5 | 11 (33.3) | 6 (50.0) | |
| > 0.5 | 22 (66.7) | 6 (50.0) | |
| Timing of combined anti-PD-1 antibody | 0.096* | ||
| Before cryoablation | 15 (45.5) | 2 (16.7) | |
| After cryoablation | 18 (54.5) | 10 (83.3) | |
| NLR | 0.096* | ||
| ≤ 2.80 | 18 (54.5) | 10 (83.3) | |
| > 2.80 | 15 (45.5) | 2 (16.7) | |
| CD8 + T/CD4 + CD25 + cell ratioѰ | 0.458 | ||
| ≤ 1.60 | 15 (62.5) | 3 (30.0) | |
| > 1.60 | 9 (37.5) | 7 (70.0) | |
| CD3-CD16 + CD56 + cells (%)Ѱ | 0.132 | ||
| ≤ 20 | 14 (58.3) | 3 (30.0) | |
| > 20 | 10 (41.7) | 7 (70.0) | |
| CD4 + CD25 + cells (%)Ѱ | 0.078* | ||
| ≤ 23 | 17 (70.8) | 10 (100.0) | |
| > 23 | 7 (29.2) | 0 (0.0) | |
| IL-6 level (pg/ml)Ѱ | 0.134* | ||
| ≤ 4.63 | 9 (45.0) | 7 (63.6) | |
| > 4.63 | 11 (55.0) | 4 (36.4) |
NLR, Neutrophil-to-lymphocyte ratio
*Fisher’s exact test
ѰA total of 34 patients have data on the level of lymphocyte subsets, and 31 patients have data on the level of Th1 and Th2 cytokines in peripheral blood before the first cryoablation